Persistence of protection against hepatitis b virus infection among adolescents vaccinated with recombinant hepatitis b vaccine beginning at birth: A 15-year follow-up study

Pediatric Infectious Disease Journal

Volumn 27, Issue 10, 2008, Pages 881-885

  Bialek, Stephanie R ^a   Bower, William A ^a   Novak, Ryan ^a   Helgenberger, Louisa ^b   Auerbach, Steven B ^c   Williams, Ian T ^a   Bell, Beth P ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Federated States of Micronesia   (Federated States of Micronesia)

^c Office of Performance Review OA/Health Resources and Services Administration   (United States)

Author keywords

Chronic hepatitis B; Hepatitis B vaccine; Micronesia; Perinatal transmission; Vaccine effectiveness

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; RECOMBINANT HEPATITIS B VACCINE; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; RECOMBINANT VACCINE;

ADOLESCENT; ANTIBODY RESPONSE; ARTICLE; BOOSTER DOSE; CHRONIC HEPATITIS; DRUG EFFICACY; FEDERATED STATES OF MICRONESIA; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVACCINATION; SEROCONVERSION; VACCINATION; BLOOD; IMMUNIZATION; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; INFANT;

ADOLESCENT; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; INFANT; MALE; VACCINES, SYNTHETIC;

EID: 54049124753     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31817702ba     Document Type: Article

References (25)

1. Centers for Disease Control and Prevention. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep. 2005;54(RR-16):1-31.
2. Ni YH, Chang MH, Huang LM, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med. 2001;135:796-800.
3. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med. 1997;336: 1855-1859.
4. Samandari T, Fiore AE, Negus S, et al. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy. Pediatrics. 2007;120:e373-e381.
5. Hammitt LL, Hennessy TW, Fiore AE, et al. Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years. Vaccine. 2007;25:6958-6964.
6. Mahoney FJ, Woodruff B, Auerbach S, et al. Progress on the elimination of hepatitis B virus transmission in Micronesia and American Samoa. Pac Health Dialog. 1996;3:140-146.
7. Dentinger CM, McMahon BJ, Fiore AE, et al. Anti-HBs persistence and response to a hepatitis B (HB) vaccine boost among Yup'ik Eskimos 22 years after HB vaccination. Presented at: Abstracts of the Infectious Diseases Society of American 43rd Annual Meeting. 2005; Abstract.
8. Watson B, West DJ, Chilkatowsky A, Piercy S, Ioli VA. Persistence of immunologic memory for 13 years in recipients of a recombinant hepatitis B vaccine. Vaccine. 2001;19:3164-3168.
9. Williams JL, Christensen CJ, McMahon BJ, et al. Evaluation of the response to a booster dose of hepatitis B vaccine in previously immunized healthcare workers. Vaccine. 2001;19:4081-4085.
10. Patel P, Armstrong G, Samandari T, Talekar S, Yamanguchi K, Kuhnert W, et al. Long term effectiveness of hepatitis B vaccine in Palau. Presented at: Abstracts of the Infectious Diseases Society of American 43rd Annual Meeting. 2004; Abstract.
11. Wu JS, Hwang LY, Goodman KJ, Beasley RP. Hepatitis B vaccination in high-risk infants: 10-year follow-up. J Infect Dis. 1999;179:1319-1325.
12. Williams IT, Goldstein ST, Tufa J, Tauillii S, Margolis HS, Mahoney FJ. Long term antibody response to hepatitis B vaccination beginning at birth and to subsequent booster vaccination. Pediatr Infect Dis J. 2003;22:157-163.
13. Dentinger CM, McMahon BJ, Butler JC, et al. Persistence of antibody to hepatitis B and protection from disease among Alaska natives immunized at birth. Pediatr Infect Dis J. 2005;24:786-792.
14. Petersen KM, Bulkow LR, McMahon BJ, et al. Duration of hepatitis B immunity in low risk children receiving hepatitis B vaccinations from birth. Pediatr Infect Dis J. 2004;23:650-655.
15. Huang LM, Chiang BL, Lee CY, Lee PI, Chi WK, Chang MH. Long-term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen. Hepatology. 1999; 29:954-959.
16. Wainwright RB, Bulkow LR, Parkinson AJ, Zanis C, McMahon BJ. Protection provided by hepatitis B vaccine in a Yupik Eskimo population-results of a 10-year study. J Infect Dis. 1997;175:674-677.
17. McMahon BJ, Bruden DL, Petersen KM, et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med. 2005;142:333-341.
18. Zanetti AR, Mariano A, Romano L, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet. 2005;366:1379-1384.
19. Orsolini P, Belloni C, Klersy C, et al. Anti-HBV neonatal immunization with recombinant vaccine. Part I. Critical appraisal for a long-lived antibody course. Vaccine. 1995;13:551-554.
20. Lu CY, Chiang BL, Chi WK, et al. Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination. Hepatology. 2004;40:1415-1420.
21. Mele A, Tancredi F, Romano L, et al. Effectiveness of hepatitis B vaccination in babies born to hepatitis B surface antigen-positive mothers in Italy. J Infect Dis. 2001;184:905-908.
22. Liao SS, Li RC, Li H, et al. Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children. Vaccine. 1999;17:2661-2666.
23. Centers for Disease Control and Prevention. Notice to readers: FDA approval of change in pediatric formulation for Recombivax HB. Morb Mortal Wkly Rep. 1999;48:34-35.
24. Lee SS, Young BW, Wong KH, Lim WL. The implication of a reduced-dose hepatitis B vaccination schedule in low risk newborns. Vaccine. 2002;20:3752-3754.
25. American Academy of Pediatrics Committee on Infectious Diseases. Recommended immunization schedules for children and adolescents- United States, 2007. Pediatrics. 2007;119:207-208.